RxDoctor Payments Data

Mark Roncone

Family · Hagerstown, MDNPI 1669982872

Payments from drug & device makers

$1,686in general payments, 2019–2025

Across 103 payments — averaging $16.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$779
  • Novo Nordisk$423
  • Lilly USA, LLC$117
  • Axsome Therapeutics, Inc.$85
  • GSK$58
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$57
  • plus $167 from 6 others

What the payments were for

  • Food & beverage$1,686100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,686 in reported general payments places this provider in the 80th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$42,978
Medicare patients
98
Services billed
492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide22$20,668
OzempicSemaglutide22$18,920
JardianceEmpagliflozin13$18,596
RybelsusSemaglutide15$15,326
Tresiba Flextouch U-100Insulin Degludec22$10,931
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$7,870
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$7,737
MyrbetriqMirabegron12$5,431
Ezetimibe56$3,069
Potassium Chloride15$2,581
Baclofen30$2,080
Paroxetine Hcl25$1,741
Phenobarbital22$1,656
Tizanidine Hcl56$1,396
Levothyroxine Sodium119$1,338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$423$34,24737 claims
Lilly USA, LLCMounjaro$117$20,66822 claims
GSKAnoro Ellipta, Trelegy Ellipta$58$15,60827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,843 family providers in Maryland.

Other family in Hagerstown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →